PL354869A1 - Inhibitor wymiany jonowej sód-wodór typu 1 w postaci krystalicznej - Google Patents

Inhibitor wymiany jonowej sód-wodór typu 1 w postaci krystalicznej

Info

Publication number
PL354869A1
PL354869A1 PL00354869A PL35486900A PL354869A1 PL 354869 A1 PL354869 A1 PL 354869A1 PL 00354869 A PL00354869 A PL 00354869A PL 35486900 A PL35486900 A PL 35486900A PL 354869 A1 PL354869 A1 PL 354869A1
Authority
PL
Poland
Prior art keywords
sodium
exchanger type
hydrogen exchanger
inhibitor crystals
crystals
Prior art date
Application number
PL00354869A
Other languages
English (en)
Inventor
Lyle Robinson Brostrom
Terrence Joseph Connolly
Zheng Jane Li
Susan Lee Orrill
Bharat Kiritkumar Shah
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL354869A1 publication Critical patent/PL354869A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL00354869A 1999-10-29 2000-10-09 Inhibitor wymiany jonowej sód-wodór typu 1 w postaci krystalicznej PL354869A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29
PCT/IB2000/001460 WO2001030759A2 (en) 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals

Publications (1)

Publication Number Publication Date
PL354869A1 true PL354869A1 (pl) 2004-03-08

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00354869A PL354869A1 (pl) 1999-10-29 2000-10-09 Inhibitor wymiany jonowej sód-wodór typu 1 w postaci krystalicznej

Country Status (44)

Country Link
EP (1) EP1224179B1 (pl)
JP (1) JP2003512455A (pl)
KR (1) KR100464526B1 (pl)
CN (2) CN1205205C (pl)
AP (1) AP2002002493A0 (pl)
AR (1) AR029402A1 (pl)
AT (1) ATE271047T1 (pl)
AU (1) AU778573B2 (pl)
BG (1) BG106729A (pl)
BR (1) BR0015275A (pl)
CA (1) CA2389020A1 (pl)
CO (1) CO5271714A1 (pl)
CZ (1) CZ20021332A3 (pl)
DE (1) DE60012208T2 (pl)
DK (1) DK1224179T3 (pl)
DZ (1) DZ3463A1 (pl)
EA (1) EA004937B1 (pl)
EE (1) EE200200227A (pl)
ES (1) ES2222923T3 (pl)
GE (1) GEP20043222B (pl)
GT (1) GT200000180A (pl)
HK (1) HK1048472B (pl)
HR (1) HRP20020366B1 (pl)
HU (1) HUP0204009A3 (pl)
IL (1) IL148581A0 (pl)
IS (1) IS6302A (pl)
MA (1) MA26840A1 (pl)
MX (1) MXPA02004358A (pl)
NO (1) NO20021821L (pl)
NZ (1) NZ517738A (pl)
OA (1) OA12080A (pl)
PA (1) PA8505501A1 (pl)
PE (1) PE20010764A1 (pl)
PL (1) PL354869A1 (pl)
PT (1) PT1224179E (pl)
SI (1) SI1224179T1 (pl)
SK (1) SK5312002A3 (pl)
SV (1) SV2002000209A (pl)
TN (1) TNSN00210A1 (pl)
TR (1) TR200201167T2 (pl)
UA (1) UA72002C2 (pl)
WO (1) WO2001030759A2 (pl)
YU (1) YU31502A (pl)
ZA (1) ZA200203295B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
CA2436539A1 (en) * 2001-01-31 2002-08-08 Pfizer Products Inc. Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
EP1472242A1 (en) * 2002-01-30 2004-11-03 Pfizer Products Inc. Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
EP1499317A1 (en) * 2002-05-02 2005-01-26 Pfizer Products Inc. Treatment of diabetes and diabetic complications with nhe-1 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002504546A (ja) * 1998-02-27 2002-02-12 ファイザー・プロダクツ・インク 虚血の治療のためのｎ−［（置換５員ジもしくはトリアザ二不飽和環）カルボニル］グアニジン誘導体

Also Published As

Publication number Publication date
HK1048472B (zh) 2005-09-16
SV2002000209A (es) 2002-07-16
EA200200416A1 (ru) 2002-10-31
ATE271047T1 (de) 2004-07-15
SK5312002A3 (en) 2003-01-09
NO20021821D0 (no) 2002-04-18
GT200000180A (es) 2002-04-11
TNSN00210A1 (fr) 2005-11-10
ES2222923T3 (es) 2005-02-16
HUP0204009A3 (en) 2004-07-28
EE200200227A (et) 2003-06-16
JP2003512455A (ja) 2003-04-02
AR029402A1 (es) 2003-06-25
AP2002002493A0 (en) 2002-06-30
DE60012208D1 (de) 2004-08-19
NZ517738A (en) 2005-06-24
CA2389020A1 (en) 2001-05-03
HK1048472A1 (en) 2003-04-04
MXPA02004358A (es) 2002-11-07
IL148581A0 (en) 2002-09-12
HRP20020366B1 (en) 2005-04-30
ZA200203295B (en) 2003-06-25
SI1224179T1 (en) 2004-10-31
OA12080A (en) 2003-08-25
DZ3463A1 (fr) 2001-05-03
EP1224179B1 (en) 2004-07-14
EA004937B1 (ru) 2004-10-28
BG106729A (bg) 2002-12-29
CN1636991A (zh) 2005-07-13
HRP20020366A2 (en) 2004-02-29
AU7441500A (en) 2001-05-08
CN1205205C (zh) 2005-06-08
CZ20021332A3 (cs) 2002-10-16
PE20010764A1 (es) 2001-07-23
BR0015275A (pt) 2002-07-16
TR200201167T2 (tr) 2002-08-21
KR100464526B1 (ko) 2005-01-03
DK1224179T3 (da) 2004-10-25
DE60012208T2 (de) 2005-07-21
EP1224179A2 (en) 2002-07-24
PA8505501A1 (es) 2003-09-05
NO20021821L (no) 2002-04-18
WO2001030759A3 (en) 2001-09-13
WO2001030759A2 (en) 2001-05-03
KR20020040918A (ko) 2002-05-30
HUP0204009A2 (hu) 2003-03-28
IS6302A (is) 2002-03-15
UA72002C2 (en) 2005-01-17
AU778573B2 (en) 2004-12-09
CN1384829A (zh) 2002-12-11
GEP20043222B (en) 2004-04-26
PT1224179E (pt) 2004-10-29
YU31502A (sh) 2004-12-31
CO5271714A1 (es) 2003-04-30
MA26840A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
EP1164345A4 (en) Heat Exchanger
IL146288A0 (en) Vla-4 inhibitor compounds
IL149097A0 (en) 4-carboxyamino-2-ethyl-1,2,3,4-thetrahydroquinoline crystal as cetp inhibitor
IL130438A (en) Heat exchanger
EP1227974A4 (en) HEAT UMTAUSCHER
GB9818185D0 (en) Heat exchanger
PL342763A1 (en) Matrix metaloprotease inhibitor
GB2333972B (en) Brazed plates cryogenic condenser
EP1136783A4 (en) HEAT EXCHANGER
GB2343643B (en) Heat exchanger
IL148581A0 (en) Sodium-hydrogen exchanger type 1 inhibitor crystals
DZ3310A1 (fr) Inhibiteurs de l'echangeur sodium-hydrogene de type 1
GB2389113B (en) B-secretase inhibitor
GB9928207D0 (en) Heat exchanger
HUP9903032A3 (en) Heat exchanger unit
IL139198A0 (en) Method for preparing sodium-hydrogen exchanger type 1 inhibitor
GB9824648D0 (en) Heat exchanger
EP1256771A4 (en) HEAT EXCHANGER
GB9926629D0 (en) Heat exchangers
GB9911761D0 (en) Heat exchanger
AU140637S (en) Cooler
GB9803871D0 (en) Heat exchanger
GB9901538D0 (en) Heat exchanger
EP1111322A4 (en) HEAT EXCHANGER
GB9827817D0 (en) Type 11 Dehydroquinase inhibitors

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)